Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Zacks Investment Research on MSN3h
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback